You are here

  • Home
  • Archive
  • Volume 9, Issue 4
  • CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation

 

Online download statistics by month:

Online download statistics by month: April 2021 to December 2025

AbstractFullPdf
Apr 2021336336170
May 202118018062
Jun 202110710738
Jul 202110910946
Aug 202110810829
Sep 2021808042
Oct 2021747453
Nov 2021919151
Dec 2021919135
Jan 2022757838
Feb 2022505025
Mar 2022494928
Apr 2022676946
May 2022737944
Jun 2022636340
Jul 2022394122
Aug 2022595934
Sep 2022737355
Oct 20229810357
Nov 2022606245
Dec 2022505019
Jan 2023515336
Feb 2023929241
Mar 2023383922
Apr 2023272722
May 2023363623
Jun 2023232310
Jul 2023373727
Aug 2023272714
Sep 202321214
Oct 2023424223
Nov 2023454512
Dec 2023454547
Jan 2024394122
Feb 2024606042
Mar 2024494961
Apr 2024474740
May 2024383934
Jun 2024414219
Jul 2024495023
Aug 2024303362
Sep 2024474822
Oct 2024585835
Nov 2024676830
Dec 2024616227
Jan 2025575730
Feb 2025464928
Mar 2025585835
Apr 2025797928
May 2025707040
Jun 2025313117
Jul 2025110
Aug 2025110
Dec 2025100
Total334633821855